List of Excipients in Branded Drug NIACIN

Generic Drugs Containing NIACIN

Company	Ingredient	NDC	Excipient
Marlex Pharmaceuticals Inc	niacin	10135-612	FD&C YELLOW NO. 6
Marlex Pharmaceuticals Inc	niacin	10135-612	FERRIC OXIDE RED
Marlex Pharmaceuticals Inc	niacin	10135-612	FERRIC OXIDE YELLOW
Marlex Pharmaceuticals Inc	niacin	10135-612	HYDROXYETHYL CELLULOSE
Marlex Pharmaceuticals Inc	niacin	10135-612	HYPROMELLOSES
Marlex Pharmaceuticals Inc	niacin	10135-612	POLYETHYLENE GLYCOL 400
Marlex Pharmaceuticals Inc	niacin	10135-612	STEARIC ACID

What are the Most Frequently-Used Excipients in NIACIN?

# Of NDCs	Excipient
8	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
12	FD&C YELLOW NO. 6
17	FERRIC OXIDE RED
17	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE
1	GLYCERYL DIBEHENATE

Niacin Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 17, 2026

Niacin is a mature, low-cost active pharmaceutical ingredient with limited composition-of-matter protection and substantial formulation differentiation potential. The strongest commercial opportunities are extended-release systems, low-flush products, combination products, orally disintegrating formats, and premium dietary supplements. Excipient selection determines dissolution, tolerability, stability, tablet performance, and the ability to support a differentiated regulatory filing.

What is the commercial opportunity for niacin formulations?

Niacin, or nicotinic acid, is used in prescription and nonprescription products for lipid management and nutritional supplementation. It is distinct from niacinamide, also called nicotinamide. Niacin can cause prostaglandin-mediated flushing, especially at immediate-release doses. That adverse effect creates a formulation problem and a market opportunity.

The commercial market divides into four segments:

Segment	Product profile	Primary formulation need	Commercial position
Immediate-release prescription	Nicotinic acid tablets	Dose uniformity, swallowability, low cost	Mature and price-sensitive
Extended-release prescription	Controlled niacin delivery	Reduced peak concentration and improved tolerability	Differentiated but clinically constrained
Dietary supplement	High-dose tablets, capsules, powders	Reduced flush, clean label, sensory performance	Large but highly competitive
Combination therapy	Niacin with statins or other agents	Release synchronization and compatibility	Narrower market, higher formulation complexity

The original prescription market for niacin has contracted because statins became standard lipid-lowering therapy and regulatory evidence weakened the role of niacin as an add-on therapy for cardiovascular risk reduction. The remaining opportunity is concentrated in patients who require alternative lipid management, products addressing triglycerides or HDL-related parameters, and consumer supplement use.

What excipient functions are most important in niacin products?

The highest-value excipient functions are release control, gastrointestinal tolerability, powder processing, taste masking, and dose uniformity.

Release-control excipients

Extended-release niacin products generally require matrix or multiparticulate systems that prevent rapid dissolution while avoiding dose dumping. Candidate excipient classes include:

• Hypromellose, particularly medium- and high-viscosity grades
• Ethylcellulose and other water-insoluble polymers
• Polyvinyl acetate-based matrix polymers
• Carbomers and acrylic acid polymers
• Hydrogenated vegetable oils and wax-based retardants
• Methacrylate copolymers for pH-dependent release
• Lipid multiparticulate carriers

A hydrophilic matrix is usually the lowest-cost development route. It can support direct compression or wet granulation, but the formulation must control hydration, gel strength, tablet dimensions, and drug loading.

A multiparticulate system provides more flexibility. Coated pellets or granules can distribute niacin throughout the gastrointestinal tract and reduce sensitivity to tablet breakup. The tradeoff is higher manufacturing cost, greater process complexity, and more demanding scale-up.

Lubricants and glidants

Niacin has high active loading in many dosage forms. High drug loading can impair flow, compaction, and tablet ejection. Magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide, and stearic acid are common formulation tools, but excessive hydrophobic lubrication can slow dissolution or weaken matrix hydration.

A commercial formulation should evaluate lubricant concentration, mixing time, and order of addition as potential critical process parameters. These variables may affect both dissolution and tablet tensile strength.

Binders and granulation aids

Povidone, copovidone, hydroxypropyl cellulose, pregelatinized starch, and maltodextrin can improve granule strength and tabletability. The preferred binder depends on the manufacturing route:

• Direct compression requires strong flow and compactibility.
• Roller compaction reduces water exposure and can simplify scale-up.
• Wet granulation can improve content uniformity but may increase processing time and moisture-related risks.

Niacin is generally compatible with standard solid-dose manufacturing, but excipient selection should account for high-dose tablets, poor powder flow, and the need to maintain release performance after compression.

Taste-masking and sensory excipients

Immediate-release niacin can have an unpleasant taste and may cause oral or gastrointestinal discomfort. Film coating, polymeric taste barriers, multiparticulate coating, and capsule-based delivery can improve acceptability.

For supplements, taste-masking systems can support gummies, chewables, stick packs, and flavored powders. The active dose may limit the practicality of low-volume delivery formats. Sugar alcohols, polyols, flavors, high-intensity sweeteners, and lipid barriers must be assessed for hygroscopicity, stability, and dose uniformity.

What formulation patents protect niacin products?

Niacin’s active ingredient is long established. Commercial protection therefore depends mainly on formulation, release profile, combination therapy, manufacturing process, and method-of-use claims.

Extended-release formulation patents

Extended-release claims may cover:

• Polymer matrices that control niacin release
• Specific dissolution profiles
• Coated particles or granules
• Reduced peak plasma exposure
• Release over defined gastrointestinal time periods
• Tablet architecture and coating composition
• Manufacturing conditions that produce the claimed release profile

A patent can remain commercially relevant even when the active ingredient is unprotected if its claims cover a clinically useful release profile or a narrow formulation architecture. The practical value depends on claim construction, design-around options, and whether the product has meaningful market share.

Historic niacin products such as Niaspan relied on extended-release formulation technology. FDA-approved generic niacin extended-release products demonstrate that the core commercial barriers associated with the original branded formulation have been reduced through generic competition and patent expiry or non-enforcement. Current patent status must be reviewed in the FDA Orange Book and relevant patent databases for the specific product and jurisdiction.[1]

Combination-product patents

Niacin has been combined with lovastatin and simvastatin in products such as Advicor and Simcor. Combination patents may claim:

• Coformulation of niacin with a statin
• Separate or synchronized release of the two actives
• Specific dose ratios
• Reduced adverse effects
• Manufacturing processes that prevent incompatibility
• Therapeutic use in dyslipidemia

These products illustrate the limits of combination strategies. A formulation can be technically protectable, but clinical adoption may decline if treatment guidelines shift or safety concerns affect the component drugs.

Method-of-use patents

Method-of-use claims may target:

• Treatment of dyslipidemia
• Reduction of triglycerides
• Elevation of HDL cholesterol
• Use in patients intolerant of statins
• Use with statins or other lipid-modifying agents
• Reduced flushing or improved adherence

Method-of-use protection is narrower than formulation protection because it depends on the claimed patient population, dose, and treatment steps. Generic manufacturers may pursue a section viii statement or omit a patented indication where permitted under the Hatch-Waxman framework.[2]

When does niacin lose exclusivity?

Niacin has no meaningful modern composition-of-matter exclusivity in the United States. The commercial exclusivity timeline has been driven by formulation and combination patents rather than by the active ingredient.

Protection category	Niacin position
Active-ingredient patent	Expired or commercially irrelevant
Immediate-release formulation	Generally mature and exposed to competition
Extended-release formulation	Historically protected; generic competition now exists
Combination products	Product-specific and largely mature
Orphan-drug exclusivity	Not a central niacin market protection
Pediatric exclusivity	Product-specific and not a principal market barrier
Biosimilar exclusivity	Not applicable
OTC supplement protection	No FDA drug exclusivity; differentiation relies on branding, formulation, and trademarks

FDA Orange Book listing status is product-specific. A listed patent can be expired, delisted, disputed, or associated with a discontinued product. Sponsors should distinguish between an Orange Book-listed patent, a live patent in a particular jurisdiction, and an enforceable claim covering a proposed product.[1]

What is the FDA regulatory status of niacin?

Prescription niacin products are approved under the Federal Food, Drug, and Cosmetic Act. Dietary supplements containing niacin are regulated under a different framework and cannot make disease-treatment claims without creating drug-related regulatory exposure.

FDA-approved prescription products have included immediate-release niacin, extended-release niacin, and niacin/statin combinations. Niaspan labeling describes extended-release nicotinic acid for lipid management and includes warnings relating to flushing, hepatotoxicity, glucose effects, and muscle toxicity when used with statins.[3]

The regulatory pathway depends on the product:

• An ANDA may be available for a pharmaceutically equivalent immediate-release or extended-release product.
• A 505(b)(2) application may support a modified-release formulation, new dosage form, new combination, or product with reliance on existing literature and FDA findings.
• A new dietary supplement generally does not receive drug approval, but its claims and ingredients remain subject to FDA supplement rules.
• A novel excipient or a new use level may require safety justification beyond the existing niacin dossier.

For extended-release products, bioequivalence and comparative dissolution are central. A formulation that produces lower peak exposure may not be interchangeable with an immediate-release product, even if total exposure is similar.

Which niacin excipients offer the strongest commercial differentiation?

The most defensible opportunities combine a measurable formulation benefit with a regulatory pathway that can support product differentiation.

Low-flush delivery systems

Niacin flushing is a major adherence barrier. Potential strategies include:

• Hydrophilic matrices that reduce rapid systemic exposure
• Delayed-release coatings
• Multiparticulates with controlled release
• Coformulation with excipients intended to modulate release
• Administration systems that reduce local gastrointestinal exposure

A sponsor should avoid claiming that an excipient alone eliminates flushing. The product must demonstrate a clinically relevant relationship between release profile, exposure, and tolerability.

Gastroretentive and site-specific systems

Gastroretentive tablets, floating matrices, and mucoadhesive systems could provide extended residence time and controlled release. These systems may support formulation patents, but they carry substantial development risk. Gastric retention can vary with food, posture, motility, and patient characteristics.

High-dose small-tablet systems

Niacin often requires a substantial dose. A multiparticulate capsule or multiple-unit tablet can improve swallowing and allow dose flexibility. This approach may also reduce the risk that a single large tablet fails its release specification.

Clean-label supplement formulations

Supplement consumers may pay a premium for:

• Plant-derived or mineral-based excipients
• Low-sugar or sugar-free dosage forms
• Vegan capsules
• Allergen-free coatings
• Reduced odor and taste
• Lower-flush positioning
• Sustained-release beadlets

These claims are commercially attractive but must be supported by compliant labeling and substantiated performance data. "Non-flush" and "no-flush" claims require particular care because some products use inositol hexanicotinate or other niacin-related compounds that may not provide equivalent nicotinic acid exposure.

How strong is the patent estate for niacin?

The niacin patent estate is moderate to weak for the active ingredient and stronger only in narrow formulation niches.

Patent category	Relative strength	Reason
Nicotinic acid composition	Low	Long-established active ingredient
Immediate-release tablets	Low	Standard excipient approaches are widely known
Extended-release matrix	Moderate	Release profile and polymer architecture can support claims
Multiparticulate delivery	Moderate	Process and coating claims may create design barriers
Low-flush formulations	Moderate	Requires clinical and pharmacokinetic support
Niacin/statin combinations	Low to moderate	Product-specific and clinically constrained
Novel excipient platform	Moderate to high	Stronger if it delivers reproducible pharmacokinetic or tolerability benefits
Manufacturing process	Moderate	Value depends on whether the process is necessary to achieve product performance

The most valuable patent claims will be performance-linked claims that define dissolution, exposure, or tolerability characteristics. Broad claims to routine excipients are vulnerable to prior-art challenges and obviousness arguments.

Which companies are challenging niacin products?

Generic manufacturers have entered the immediate-release and extended-release niacin markets. The principal competitive threat is therefore not a single late-stage challenger but a group of ANDA sponsors competing on price and supply reliability.

The competitive landscape includes:

• Generic manufacturers of immediate-release niacin
• Generic manufacturers of extended-release niacin
• Branded supplement companies
• Specialty companies selling low-flush or sustained-release niacin
• Contract manufacturers offering private-label niacin products
• Companies developing combination lipid products

Paragraph IV risk is most relevant when a sponsor seeks approval for a product covered by a live Orange Book-listed patent. For mature niacin products, the larger commercial issue is usually abbreviated approval, substitution, manufacturing scale, and channel access rather than prolonged patent litigation.[1,2]

What generic launch scenarios exist for niacin?

A generic launch can follow several paths:

1. An immediate-release ANDA competes directly on price and availability.
2. An extended-release ANDA uses comparative pharmacokinetic and dissolution data to establish equivalence.
3. A 505(b)(2) sponsor introduces a modified-release product with a new label or dosage form.
4. A supplement company launches a branded sustained-release product without seeking prescription-drug approval.
5. A combination-product sponsor uses separate tablets, capsules, or co-packaging to avoid complex coformulation requirements.

The lowest-risk commercial entry is usually a conventional immediate-release tablet. The higher-margin opportunity is a differentiated extended-release or low-flush product, but that route requires clinical evidence, more complex manufacturing, and stronger patent strategy.

What manufacturing and intellectual-property barriers affect niacin?

Manufacturing barriers are more important than raw-material access. Nicotinic acid is widely available, and API cost is unlikely to create a durable competitive advantage.

Key barriers include:

• Achieving uniform drug distribution at high loading
• Controlling dissolution across scale
• Avoiding dose dumping
• Maintaining coating weight and film integrity
• Managing polymorph, particle-size, and bulk-density differences
• Controlling moisture and tablet hardness
• Demonstrating stability under accelerated conditions
• Reproducing pharmacokinetic performance between batches
• Establishing supplier qualification and API impurity controls

IP protection can cover excipient ratios, coating layers, process parameters, particle-size specifications, dissolution windows, and product-by-process limitations. The strongest strategy combines a formulation patent with manufacturing know-how that is difficult to replicate from the public patent disclosure.

How does niacin compare with niacinamide and other vitamin B3 products?

Attribute	Niacin	Niacinamide
Chemical identity	Nicotinic acid	Nicotinamide
Lipid-lowering effect	Established pharmacologic effect at high doses	Does not provide the same lipid-lowering profile
Flushing	Common at pharmacologic doses	Generally does not cause typical niacin flushing
Primary market	Prescription lipid therapy and supplements	Nutritional supplements, dermatology, cosmetics
Formulation opportunity	Release control and tolerability	Stability, skin delivery, and supplement formats
Patent opportunity	Modified release and low-flush products	Topical delivery, combination products, and cosmetic formulations

Substitution between the two compounds is not scientifically or commercially interchangeable. Product labeling must identify the precise active form and amount.

Key Takeaways

• Niacin’s active ingredient is mature; commercial differentiation depends on formulation and delivery.
• Extended-release, low-flush, multiparticulate, and high-dose swallowability systems offer the strongest opportunities.
• Hydrophilic polymers, ethylcellulose, acrylic polymers, lipid carriers, binders, and taste-masking coatings are the principal excipient platforms.
• Formulation patents should claim measurable dissolution, exposure, tolerability, or manufacturing performance.
• Generic competition limits the value of conventional immediate-release and legacy extended-release products.
• Biosimilar risk does not apply because niacin is a small-molecule drug.
• FDA pathway selection depends on whether the product is an equivalent generic, a modified-release 505(b)(2) product, or a dietary supplement.
• The main commercial barriers are clinical differentiation, reproducible dissolution, scale-up, and channel access rather than API availability.

FAQs About Niacin Excipient and Patent Strategy

Can a niacin formulation receive patent protection without a new active ingredient?

Yes. A sponsor can pursue patents covering controlled release, multiparticulate architecture, excipient ratios, dissolution profiles, manufacturing processes, or specific therapeutic uses.

Is sustained-release niacin automatically equivalent to extended-release niacin?

No. Release terminology does not establish pharmaceutical equivalence. FDA approval depends on the product’s dosage form, release characteristics, labeling, and bioequivalence evidence.

Is inositol hexanicotinate a substitute for prescription niacin?

No. It is a different niacin-related compound, and its conversion to active nicotinic acid may differ from prescription niacin. It should not be presented as therapeutically interchangeable without supporting evidence.

Can a niacin supplement claim to reduce cholesterol?

Disease-treatment claims can cause a supplement product to be regulated as a drug. Claims must remain within the applicable FDA framework and be supported under the relevant labeling requirements.[4]

What is the best excipient platform for a new niacin product?

A hydrophilic extended-release matrix is usually the most practical starting point. Multiparticulate coating is more flexible and may offer stronger differentiation, but it requires greater process control and development investment.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/regulatory-information

3. U.S. Food and Drug Administration. (2019). Niaspan prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

4. U.S. Food and Drug Administration. (2023). Structure/function claims, small entity compliance guide. https://www.fda.gov/food/food-labeling-nutrition/structurefunction-claims-supplements